Lori Rink, PhD

Gastrointestinal Stromal Tumors (GIST) are the most common sarcomas of the gastrointestinal tract.  These tumors are characterized by near-universal expression of the receptor tyrosine kinase (RTK) KIT, and the majority of GIST harbor constitutively active mutant isoforms of KIT (70-80%) or the related RTK, PDGFRA (5-7%). The ~10-15% of GIST that lack mutations in these genes often exhibit genetic or epigenetic deficiencies in the succinate dehydrogenase (SDH) complex of the respiratory chain, and are referred to as SDH-deficient (SDH-d). Therapeutic targeting of GIST with the front-line RTK inhibitor, imatinib mesylate (IM) along with four other FDA approved agents (sunitinib, regorafenib, ripretinib and avapritinib) has transformed therapy for advanced, unresectable GIST. Although these RTK inhibitors are effective in most GIST, primary and acquired resistance remains a significant clinical obstacle.  Our research is focused on elucidating mechanisms of resistance to these RTK inhibitors and identifying and evaluating new therapeutic targets in preclinical models of GIST.

A role for AKT in drug resistance in GIST

Following a period of response to RTK therapy, the majority of tumors ultimately develop resistance, mainly through the acquisition of secondary RTK mutations and the activation of bypass RTK downstream pathways, such as the PI3K/AKT pathway. Unfortunately, once all approved lines of therapy have failed, patients with advanced GIST are then left without any further treatment options. Therefore, a significant problem in the treatment of GIST is preventing the development of acquired resistance to the most potent first-line therapeutic agent, IM.

We demonstrated AKT activation to be a hallmark of IM resistance in GIST. The presence of an additional therapeutic agent could potentially suppress the growth and survival of a clone of cancer cells, which have developed resistance to IM. Simultaneous targeting of AKT in addition to inhibiting KIT with IM has potential to be a promising strategy to prevent the development of secondary resistance to IM. Our group has previously shown significantly enhanced combination effects of IM with MK-2206, an oral pan-AKT inhibitor, in an IM-sensitive xenograft model in vivo, as measured by extended disease stabilization and improved survival. We are currently evaluating the efficacy of several new AKT inhibitors in both IM-sensitive and resistant preclinical GIST models and interrogating the mechanism of synergy resulting from this drug combination.

Kinome profiling in GIST to identify new targets

GIST has three major genotypic subtypes: KIT mutant, PDGFRA mutant and SDH-deficient GIST. Mutational subsets confer different natural histories and primary response to IM. Limited options exist for those patients whose disease is refractory to primary treatment. Therefore, there is an urgent need to identify novel targets to provide additional therapeutic options and combinations for refractory GIST. Inhibition of cancer-promoting cell signaling pathways by targeting additional protein kinases active in GIST may provide these options. Global kinome profiling has the potential to identify critical signaling networks and reveal protein kinases that are essential in GIST. In collaboration with Dr. James Duncan (Cancer Biology Program, Fox Chase Cancer Center), we explored the majority of the kinome in GIST specimens from the three most common molecular subtypes to identify novel kinase targets using multiplexed inhibitor beads and mass spectrometry. Using this proteomics approach, we demonstrated that the three GIST subtypes have distinct kinome profiles, and identified kinases that are universally activated in all GIST, as well as kinases that are unique to each subtype. We are currently working to evaluate the identified hits as potential novel targets in GIST.

Identification of Wee1 as a target in combination with avapritinib for GIST treatment

Wee1, gatekeeper of the G2/M cell cycle checkpoint, was shown to be highly abundant in GIST compared to normal tissue as part of our kinome profiling study. Loss-of-function studies targeting Wee1 in KIT and PDGFRA-mutant GIST cell lines revealed an essential role for Wee1 in GIST cell proliferation, suggesting Wee1 as a plausible drug target in GIST. We demonstrated enhanced drug combination effects between avapritinib and MK-1775 (Wee1 inhibitor) in both KIT and PDGFRA-driven GIST cell lines using two-dimensional (2D) and three-dimensional (3D) in vitro viability studies. Mechanistic studies revealed that this drug combination led to increased DNA damage and a loss of cell cycle regulation, decreasing time for DNA damage repair, and ultimately causing increased apoptosis. In vivo studies demonstrated that dual inhibition of Wee1 and KIT/PDGFRA in GIST xenografts provided impressive, extended disease stabilization and improved survival.

Development of novel patient-derived xenograft (PDX) models of GIST.

A limitation to the study of GIST is the lack of available models to study in the laboratory. There are limited cell lines that have been developed, and attempts at developing them have been very challenging. One method to overcome this difficulty has been to implant tumor tissue removed at the time of surgery and directly implant the tissue into mice. This approach, called PDX models, is one that we have been taking in collaboration with our surgical oncology colleagues. To date we have successfully developed eight models. Once developed, this approach allows for testing of novel drugs and drug combinations in animal models representing different genotypes to expand the available models for further preclinical testing of novel agents and or combinations of agents.